Will Kaback
speaker
1,313 appearances
13 recordings
1 series
first heard Aug 2026
last heard 5d ago
Will Kaback’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 13 in all, peaking in Sep 2026 with 12.
Appearances
Thanks, Audrey.
Okay, here are today's quick hits.
Number one, a federal judge ordered the Trump administration to restore White House press credentials to CNN, MSNOW, and Politico reporters, finding that the administration's ban is likely unconstitutional.
Number two, Iranian President Mazood Pazeshkian addressed the United Nations General Assembly, criticizing the U.S.
and Israel for attacking his country and saying that it will fight the war, quote, until our last breath.
Number three, Chinese President Xi Jinping arrived in Washington, D.C.
for a state visit hosted by President Donald Trump.
Shortly after Xi's arrival, the U.S.
and China announced an extension of their trade truce until January 2027.
Number four, the 10-year treasury yield, the annual interest rate paid by the federal government to investors who own 10-year debt notes, rose to 5.14% on Wednesday, the highest rate since July 2007.
And number five, acting Navy Secretary Hung Kao informed lawmakers that eight sailors assigned to the USS Abraham Lincoln Aircraft Carrier Strike Group attempted suicide during the ship's recent deployment to the Middle East.
In recent years, use of new weight loss medications has risen in the United States.
A 2026 Gallup poll found that a record 11% of U.S.
adults are taking GLP-1 medications for weight loss, up from 3% in 2024.
Furthermore, high-profile figures like Illinois Governor J.B.
Pritzker and decorated tennis player Serena Williams have extolled their experiences taking the drug.
The rising prevalence of GLP-1 use for weight management has sparked a debate over the potential impact on health and wellness in the United States.
GLP-1s, or glucagon-like peptide 1 agonists, are a class of medication that primarily treats type 2 diabetes and obesity.
GLP-1 agonists mimic the GLP-1 hormone, which is made in the small intestine, to trigger insulin release, slow down digestion, and increase the feeling of fullness after eating.
The Food and Drug Administration first approved GLP-1s for medical use in 2005, but their popularity has increased significantly in recent years with the introduction of brand names like Ozempic and WeGoVie.
Showing 1–20 of 1,313 · page 1 of 66
Next →